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The aim is to investigate the radiosensitivity of noninfected cultured human glioma cells to ascertain that intracutaneously
administered cells are viable enough to produce interferon-g but not able to proliferate. Cell cultures were established from five
patients undergoing brain tumour surgery. By karyotyping, we found four malignant (three glioblastoma multiforme (GBM), one giant
cell glioma) and one normal. The cells were irradiated with
137Cs-g rays at absorbed dose levels of 0, 20, 40, 60, 80, 100 and 120Gy.
The fraction of viable cells was examined by MTT incorporation assay. The average of the data obtained from three GBM cell cultures
was fitted to an exponential model. The parameters were: extrapolation number n¼0.8570.10, mean lethal dose
D0¼12.473.2Gy and an additional uncertainty parameter dS¼0.1470.03. By setting dS¼0, the corresponding values of the
parameters were n¼0.8670.16 and D0¼30.078.1Gy. The rate of proliferation was examined by
3H-thymidine incorporation. The
average of the proliferation data obtained from three GBM cell cultures was fitted to an exponential model yielding n¼0.94370.005
and D0¼5.870.5Gy for dS¼0.05770.005, and by setting dS¼0, n¼1.0070.02 and D0¼8.471.6Gy. No outgrowth of plated
cells was observed after 4 weeks at an absorbed dose of 100Gy. This absorbed dose is recommended for irradiation of 2 10
6
glioma cells used for clinical immunisation.
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The most malignant type of brain tumours, glioblastoma multi-
forme (GBM)– or astrocytoma grade IV (according to the WHO
classification) as well as giant cell gliomas (GCGs) are among the
most therapy-resistant human cancers (Salford et al, 1988). The
tumour front of this tumour, consisting of highly proliferating
cells, grows by progressively killing the surrounding normal brain
cells, neuronal and glial. In autopsies, glioma cells, single or in
small clusters, are demonstrated in the whole brain, including the
brain stem of patients with subcortical tumours (Burger et al,
1988). Radiotherapy and chemotherapy have hitherto proven not
to be efficient enough for cure (Sheline, 1977; Stenning et al, 1987).
We believe that the key for success in the treatment of GBM
would be a method to reach the migrating glioma cells, also called
‘guerrilla cells’. Such an efficient treatment regime could be
‘immunogenic tumour therapy’. In a brain tumour rat model,
440% of the rats survived 430 weeks after immunisation with
syngeneic brain tumour cells transfected with the rat interferon-g
(IFN-g) gene. The cells were injected subcutaneously 1 to 3 days
after the inoculation of nontransfected glioma cells in the brain of
the rats. If not treated with immunisations, these animals develop
lethal intracerebral gliomas within 3 to 4 weeks (Visse et al, 1999).
In the translation of this model to the human situation, it is of
great importance for safety and efficiency to know the radio
sensitivity and survival characteristics of the cultivated cells. We
have investigated the efficiency of sterilisation of human malignant
brain tumour cells in preparation for the clinical research
programme Brain ImmunoGene Tumour Therapy (‘BRIGTT’)
approved by the Medical Products Agency in Sweden (Salford
et al, 2002). The immunisation will take place by administration of
radiation-sterilised autologous tumour cells that have been
genetically engineered to produce human IFN-g and green
fluorescent protein as immune enhancers, in the dermis of the
upper arm. It is important that the radiation dose used for
sterilisation of these cells will inhibit the proliferation of the
genetically modified tumour cells but not block the metabolic
activity and the production of recombinant proteins.
Previous studies of the intrinsic cellular radiation sensitivity of
noninfected human glioblastoma cell lines have used low radiation
dose levels in order to investigate the shoulder of the survival
curves (Malaise et al, 1986; Taghian et al, 1992). In the present
study, however, we examine the radiation survival characteristics
at much higher radiation dose levels. Thus, our aim is to
investigate the radiation characteristics of noninfected cultured
human glioma cells to ascertain that intracutaneous administered
cells are viable enough to produce IFN-g but not able to proliferate.
In this study, we also included an apparently normal brain cell Received 4 July 2003; revised 2 October 2003; accepted 8 October 2003
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lculture (as monitored by karyotyping) from a human GBM
specimen in order to give some information on the effect of
irradiation in normal brain cells. In theory, normal cells can
induce autoimmune reactions and should not be present when
genetically modified cells are injected in the patients.
MATERIALS AND METHODS
Media
Cells were cultured in complete Iscove’s modified Dulbecco’s
medium (IMDM) medium (Life Technology, Paisley, UK) supple-
mented with 15–20% foetal calf serum (FCS) (Sigma Chemical Co.,
St Louis, MO, USA), penicillin (Labora, Malmoe, Sweden),
streptomycin (Labora, Malmoe, Sweden), Na pyruvate (Life
Technology), MEM (nonessential amino acids) (Life Technology,
Paisley, UK) and a-thioglycerat (Sigma).
Lysis solution used in the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay: 20% wv
 1 of SDS
was dissolved at 371C in a solution of 50% of DMF (N,N-dimethyl
formamide) and demineralised water, pH was adjusted to 4.7 by
adding 2.5% of 80% acetic acid and 2.5% 1 M HCl.
Cells
Cells were obtained from cell cultures of biopsies from five patients
with malignant brain tumours – four with GBM and one with a
GCG. From each patient undergoing surgical removal of the brain
tumour, 100–3000mg of tumour tissue was collected, minced and
digested with an enzyme solution containing 0.5mgml
 1 collage-
nase type VIII (Sigma) and 20mgml
 1 DNAse I (Sigma) dissolved
in IMDM without FCS. After 3 20min of digestion at 371C with
continuous gentle agitation, the resultant cell suspension was
centrifuged at 150g for 15min. The pellet was suspended with
10ml complete IMDM medium and seeded on Primaria plastic
tissue culture flasks (25cm
2, Labora, Malmoe, Sweden) to be kept
in a humidified incubator at 371C in 10% CO2.
The cells were cultivated for 2–4 months before they were
karyotyped at the Department of Clinical Genetics at Lund
University Hospital, Sweden. Human malignant glioma cells grow
rather slowly in tissue cultures. The doubling time is between 70
and 100h for most primary glioma cell cultures. On the other
hand, normal cells in tissue culture have a doubling time of
approximately 24h. Owing to these circumstances, cultures from
human brain tumour specimens are initially overgrown by normal
cells, for example, endothelial cells, fibroblasts and other
nonmalignant cells. After a few months, in vitro culture normal
cells cease to divide and the malignant cells will prevail. It was
possible to establish the growth of pure malignant glioma cells in
more than 50% of the cultures. The cells from the fourth GBM
patient had not reached a malignant stage and only cells with
normal karyotype grew in this culture when they were harvested.
Karyotyping
The five cultures were called GCG (originating from GCG patient #
1212), with the karyotype: 41–44,XX,del(2)(p22–23),del(4)(p11),-
del(5) (p11),þ7, 10, 11, 13, 16, 17,add(22)(q13), þmar
[cp5] (14 cells, all aberrant), GBM1 (originating from patient #
1141), with the karyotype 108–121, XX, add(1)(q21), del(1)(q12),
add(6)(q?15), add(19)(p13), þ?der(?)t(?;10)(?;q11), inc[cp4] (11
cells, all polyploid and complex), GBM2 (originating from patient #
1151), with the karyotype 69–77, XXY, þY, þ1, add(1)(p11) 2,
 4, þ7, þ7, þ7, þ8, þ9, add(9)(p11) 2,  10, þ13,  14,
 15,  17,  18, der(19)t(?17;19)(q21;q13), þ20, þ21, þ22,
þ2mar[cp] (11 cells, all aberrant), GBM3 (originating from
patient # 1160), with the karyotype 63–66, X, del(1)(q21),
þ?add(3)(q11), der(4;14)(q10;q10), add(11)(q23), add(12)(p11),
þ?14, þmar, inc[cp2]/125, X, ?del(1)(q21), add(12) (p11), inc[2]
(11 cells, all aberrant) and normal cells (N1, originating from GBM
patient # 1211) 14 cells, with normal karyotype.
Irradiation
The cells were transferred from the culture flasks to 15ml
centrifuge test tubes (Nanclon, Nalge NUNC International, Den-
mark) and stored in a melting ice bath before irradiation with
137Cs-g rays using a Gammacell 2000 (Mlsgaard Medical, Ris,
Denmark) source at a dose rate of 4.0Gymin
 1. During the
irradiation, the cells were kept at room temperature and the cell
density was 2 10
4 cellsml
 1. The cells were kept in a serum-free
medium (IMDM-0) that does not allow the cells to grow during the
procedure. The cells were irradiated to 0, 20, 40, 60, 80, 100 and
120Gy that correspond to irradiation times up to 30min. In order
to keep the cells at room temperature for equal time, all samples
were kept for 30min at room temperature before they were placed
in a melting ice bath. Nonirradiated control cells were kept in
15ml centrifuge test tubes in serum-free medium (IMDM-0) and
were stored for 30min at room temperature and on melting ice
during the procedure.
MTT assay
The viability condition of irradiated cells is obtained from studies
of how the mitochondria in living cells transforms MTT to
formazan salt (Denizot and Lang, 1986), which is insoluble in the
medium. The salt can be dissolved by sodium dodecyl sulphate
and the absorption at 570nm is closely correlated to the number of
viable cells in the sample. After irradiation, the cells were plated in
flat-bottomed 96-well plates (Nanclon), 5000 cellswell
 1, and kept
in a humidified incubator with 10% CO2 at 371C for 5 days. Then,
25ml of MTT stock solution (5mgml
 1) was added to each well,
followed by incubation at 371C and 10% CO2 for 2h. After 2h of
incubation, 100ml of lysis solution was added to each well and
further incubation at 371C and 10% CO2 was required for at least
6h. The optical densities at 570nm were measured using an ELISA
reader (Multiskan MS, Labsystems, Finland).
3H-thymidine incorporation in DNA
Incorporation of tritium-labelled thymidine in DNA is used to
study the rate of DNA synthesis and thus the rate of the cell
division (proliferation) (Yoffey et al, 1959, 1961; Devik, 1962;
Quarteyp and Yoffey, 1968). The irradiated tumour cells were
plated in flat-bottomed 96-well plates (Nanclon, Nalge NUNC
International, Denmark), 5000 cellswell
 1, and kept in a humidi-
fied incubator in 10% CO2 at 371C for 5 days. An activity of 0.5mCi
(18.5kBq)
3H-thymidine (Amersham, UK) was thereafter added to
each well, followed by incubation of the cells for 6h in 10% CO2 at
371C. The samples were harvested, using double-distilled water to
lyse the cells, and the lysate was filtrated through glass fibre
membranes (Wallace Oy, Finland) on which materials of high-
density molecules were collected. In each assay, the membranes
were dried and the radioactivity was measured in a liquid
scintillation counter (Wallace Microbeta, Wallace Oy, Finland).
The analysis of each sample was performed in six replicates. The
recorded count rate (c.p.m.) value is a measure of the number of
cells that have undergone cell division or DNA repair during the
6h of incubation with
3H-thymidine.
Plating efficiency
Approximately 1 10
6 cells from GCG, GBM1, GBM2, GBM3 and
N1 cultures were irradiated with an absorbed dose of 100Gy. The
irradiated cells were plated in tissue culture flasks with complete
IMDM medium and were incubated at 371C and in 10% CO2 for up
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lto 4 weeks. The cells were followed by optical inspection about
every second day under an inverted phase-contrast microscope
during a 4-week period. In these adherent tissue cultures,
nondividing cells flatten out on the surface and look greyish and
dark. Actively proliferating cells are lighter and if in mitosis, they
round up and appear radiant. When the cells die, they float up to
the surface of the medium and disintegrate. Hence, the total
number of cells in the irradiated cultures decreases over time and
after about 3–4 weeks, there were very few proliferating cells to be
observed.
Cell survival model
In the present work, we are mainly interested in studying the
survival of cells exposed to large absorbed doses 420Gy. The
survival of mammalian cells in vitro irradiated with large absorbed
dose is modelled according to an exponential model (Tubiana et al,
1990).
In our experiments, however, we find a certain fraction of cells
proliferating after having received absorbed doses of 20Gy and
above. Most models of cell survival do not take into account this
fraction of cells, which are still proliferating at very high values of
the absorbed dose. Therefore, we add a term dS to the traditional
equation of survival fraction S as follows:
S ¼ ne D=D0 þ dS ð1Þ
where S is the survival fraction, D0 is the mean lethal dose for
which the survival fraction S¼1/e, D is the administered absorbed
dose, n is the extrapolation number at D¼0 that might be
interpreted as the number of sublethal events and dS is the
extrapolation number at infinite absorbed dose that might be
interpreted as either a methodological uncertainty number or a
fraction of highly radioresistant cells.
The survival fraction of the MTT assay gives the probability
or fraction of viable cells, W(V) that includes both apoptotic
and proliferating cells. On the other hand, the survival ratio of
the
3H-thymidine assay gives the fraction of cells proliferating (L)
and thus also viable (V). This fraction or probability can be written
as W(V-L). To guarantee sterile conditions, we wish to evaluate
the probability of viable cells able to proliferate after irradiation.
This is equal to the conditional probability W(L|V) of cell
proliferation (L) given that the cells are viable (V) after the
irradiation exposure (Lindgren, 1976), which is well defined only
when W(V)40:
WðLjVÞ¼
WðL \ VÞ
WðVÞ
ð2Þ
where W(L|V) is the probability of proliferation of cells still viable
after radiation, W(L-V) is the probability of cells to proliferate
and being viable, that is, S(
3H-thymidine) and W(V) is the
probability of cells being viable, that is, S(MTT).
The absorbed dose that corresponds to a certain probability,
W(L|V), of proliferation of cells still viable after radiation equals
the exponential term in equation (1) that can be expressed as
follows:
WðLjVÞ¼e DWðL=VÞ=D0 ¼
S   dS
n
ð3Þ
Thus the absorbed dose, D W(L|V), which corresponds to a certain
probability, W(L|V) becomes
DWðL=VÞ ¼ D0   lnð1=WðL=VÞÞ ð4Þ
From this equation the absorbed dose for sterile condition, that is,
W(L|V)¼10
 6 (w¼E 6) can be given as:
Dw¼E 6 ¼ D0 lnð106Þ D0   13:8 ð5Þ
RESULTS
Cells from four malignant brain tumour cultures (GCG, GBM1,
GBM2 and GBM3, respectively) and one from a normal brain cell
culture (N1) were irradiated at absorbed doses of 20, 40, 60, 80, 100
and 120Gy at a dose rate of 4.0Gymin
 1. After irradiation, the
cells were plated in 96-well plates (5000 cellswell
 1) and evaluated
either by incorporation of
3H-thymidine or by an MTT assay at 5
days after irradiation.
3H-thymidine incorporation assay
The cell division examined by the
3H-thymidine incorporation
assay is given as the count rate of
3H plotted as a function of the
absorbed dose. The surviving ratios from the
3H-thymidine
incorporation for the different cell cultures are plotted against
the absorbed dose in Figure 1a for the individual cell lines. The
surviving ratio of normal cells and the average of GBM cell lines
are displayed separately in the same figure. The incorporation of
3H-thymidine reflects both the unscheduled DNA synthesis (DNA
repair) as well as DNA synthesis reflecting cells entering the S
phase. The incorporation of
3H-thymidine is measured by a ‘6h
pulse labelling’ 5 days after the irradiation. In the cell survival
experiments, we observed a dramatic reduction in the number of
cells about 1 week after irradiation. The results obtained by fitting
the data of
3H-thymidine incorporation assay to the exponential
model for cell survival (equation (1)) are given in Table 1.
MTT assay
The viability, that is, surviving fractions derived from the recorded
optical densities of the MTT assay, of the different cell cultures, are
plotted against the dose in Figure 1b. In Figure 1b the surviving
fraction values of normal (N1) and the four malignant cell cultures,
GBM1, GBM2, GBM3 and GCG are given for different doses
between 0 and 120Gy in 20Gy increments. The figure shows that
for all these cell cultures, there is a decreasing fraction of viable
cells with increased absorbed dose. In Figure 1b, we have also
plotted the average surviving fraction of all the GBM tumour cell
cultures, whereas the normal cell culture is displayed separately.
The measurement is recorded at 5 days after irradiation and at this
time, a certain number of cells are no longer viable, for example,
detectable as physiological functional cells. Since the amount of
viable cells is correlated to the absorption of the dissolved
formazan salt in the MTT assay, the optical density plotted in
Figure 1 gives the viability as a function of the absorbed dose. The
results obtained by fitting the data of the MTT assay to the
exponential model for cell survival (equation (1)) are given in
Table 2.
Plating efficiency
In order to further evaluate if a sterilisation dose of 100Gy was
sufficient, one million cells were irradiated and plated in tissue
culture flasks. The cells were kept in the flasks surveyed by
photographing in an inverted phase-contrast microscope repeat-
edly during up to 3 or 4 weeks after irradiation. In all cases, the
number of viable cells decreased with time. Photographs were
taken at 1, 7, 14 and 20 days after irradiation with
137Cs-g rays. In
Figure 2, pictures of a typical culture (GBM2, irradiated with an
absorbed dose of 100Gy) are displayed. The upper left picture (A)
of Figure 2 clearly shows the confluent cells and their nuclei at day
1 after irradiation. The cells seem to be viable, although the
proliferation is very limited since very few mitotic cells can be
detected. The upper right picture (B) of Figure 2, taken at day 7,
shows dark clusters of dead or dying cells and a few intact living
cells are seen as well. Picture (C) in the lower left corner of Figure 2
that is taken at day 14 shows almost no viable cells and thus no
Radiation sterilisation of brain tumour cells
C Baure ´us-Koch et al
50
British Journal of Cancer (2004) 90(1), 48–54 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lproliferating cells. Dark clouds of dead cells dominate this picture.
Finally, the lower right picture (D) of Figure 2, taken at day 20 after
irradiation, shows no or very few cells that we can diagnose as
viable among the dark clouds of dead cells.
DISCUSSION
We have investigated the efficiency of the sterilisation of human
malignant brain tumour cells in connection to a clinical study of
‘Brain ImmunoGene Tumour Therapy’ BRIGTT (Salford et al,
2002). In the present investigation, we studied nontransfected
human glioma cells irradiated with
137Cs-g rays at different
absorbed doses (20, 40, 60, 80, 100 and 120Gy).
The cell viability was studied by applying the MTT assay to cells
irradiated at 20–120Gy in 20Gy intervals. The results of optical
density measurements of the MTT assay were plotted as a function
of absorbed dose and the data were fitted to an exponential model
(equation (1)), which resulted in the parameters dS, n and mean
lethal dose D0.
A constant fraction, dS, of ‘viable cells’ at high absorbed doses,
was introduced to account for the fraction of cells still viable after
an absorbed dose of 20Gy or higher. The data for the extrapolation
number at D¼0 and mean lethal dose D0 obtained by fitting the
MTT assay data are displayed in Table 2. Diagrams with both the
constant fraction dS taken into account and with dS assumed to be
zero are displayed in the figure. The parameters dS, extrapolation
number n and mean lethal dose D0 obtained from the MTT assay
were compared for cells from different patients. The mean values
of the various parameters in the model with dS taken into account
for the malignant karyotyped cells were determined to be
n¼0.8570.06 and D0¼12.473.2Gy at dS¼0.1470.03. In case
the value of dS was assumed to be zero, the corresponding mean
values were determined to be n¼0.8670.16 and
D0¼30.078.1Gy. The viability parameters of normal cells were
found to be quite different between malignant karyotype cells and
the cells of normal karyotype.
The cell proliferation was determined by the use of the
3H-
thymidine incorporation assay. The count rate data, from
measuring
3H in a scintillation counter, were plotted as a function
of absorbed dose and then fitted to an exponential model
(equation (1)). The values of the
3H-thymidine assay for the
extrapolation number n and mean lethal dose D0 are displayed in
Table 1, both with dS taken into account and with the value of dS
assumed to be zero.
The parameters dS, extrapolation number n and mean lethal
dose D0 obtained from the
3H proliferation study was compared
for cells from different patients. In this comparison, we found
no apparent difference between malignant karyotype cells
and the cells of normal karyotype. In practice, this does not
matter because there are no normal cells administered to the
patient at the immunisation in order to avoid the risk of
autoimmune reactions.
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Figure 1 (A) Surviving ratio from
3H-thymidine incorporation as a
function of absorbed dose for the irradiated cells of patients GM 1, GM 2,
GM 3, GC 1 (of malignant karyotype) and N1 (of normal karyotype). (B)
Surviving fractions from MTT assays as a function of absorbed dose for the
irradiated cells from patients GMB 1, GMB 2, GMB 3, GC (of malignant
karyotype) and of normal karyotype. Keys to the abbreviations are given
under the paragraph ‘Karyotyping’.
Table 1 Radiation sensitivity parameters n, D0 and dS for irradiated cells obtained from fitting
3H-thymidine incorporation assay data of cells from patients
GBM1, GBM2, GBM3, GCG (malignant karyotyped) and N1 (normal karyotyped)
Uncertainty factor
dS¼0 dSa0
Fitting parameters nD 0 (Gy) dSn D 0 (Gy)
Cell lines
GBM1 1.00070.013 8.9871.78 0.06370.002 0.93770.003 6.2970.25
GBM2 1.00070.017 7.2171.90 0.05470.007 0.94670.009 3.3973.35
GBM3 1.00070.015 8.7971.37 0.06070.005 0.94070.006 8.7971.37
Average GBM1–3 1.00070.016 8.3871.62 0.05770.005 0.94370.005 5.7670.50
GCG 1.00070.001 4.2270.55 0.00670.001 0.99470.001 3.3670.48
N1(Normal) 1.00070.003 6.4770.54 0.01270.002 0.99870.002 5.8670.22
The average GM values are calculated from patients GBM1, GBM2 and GBM3.
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the model for the malignant karyotyped GBM cells in this study
were determined to be n¼0.94970.004, D0¼5.870.6Gy and
dS¼0.05770.005. In the case where the value of dS¼0, the values
of the extrapolation number and the mean lethal dose were
n¼1.0070.02 and D0¼8.3871.62Gy, respectively.
Other previously documented studies of the intrinsic cellular
radiation sensitivity of noninfected human glioblastoma cell lines
have mostly used irradiation at absorbed dose levels below 12Gy
(Malaise et al, 1986; Taghian et al, 1992; Allam et al, 1993; Taghian
et al, 1995; Wilkins et al, 1996; Budach et al, 1997; Raaphorst et al
1999). The first study of five human glioma cell lines resulted in
the mean lethal dose D0¼1.470.4Gy (Malaise et al, 1986). A
second study of 10 human glioblastoma cell lines in vitro resulted
in the mean lethal dose D0¼1.670.5 (Taghian et al, 1992, 1995)
and a third study of 11 human glioblastoma cell lines in vitro
resulted in a mean inactivation dose of D0¼2.070.6 (Allam et al,
1993). Radiation survival curves for U373MG and U87MG human
glioma cells, under the condition of high-dose rate up to 10Gy
resulted in the mean lethal dose values of 1.0 and 0.7Gy,
respectively (Wilkins et al, 1996; Raaphorst et al 1999). The
results obtained in our study from three new GBM cell cultures
yielded the mean lethal (nonproliferating) dose D0 in the order of
6–8Gy. We have not found any radiosensitivity parameters in the
literature at such a high absorbed dose as 100Gy. In a recently
published study, however, two human cell lines (GaMG and U-
87MG) were irradiated up to 60Gy. Their results indicate that
irradiated malignant glioma subpopulations survive at this high
absorbed dose, which is in agreement with our findings of a
fraction of very radio-resistant cells (Gliemroth et al, 2003).
The experiments in the present investigation have been
performed at absorbed doses up to 120Gy. By using the D0, n
and dS data for cell proliferation (
3H-thymidine) and cell survival
(MTT), it is possible to estimate the probability of proliferated and
surviving cells, respectively, by equation (3).
The number of cells injected into the patient is about 2 10
6 for
each immunisation procedure. We want to estimate the absorbed
dose for which there is only one single proliferating cell present,
that is, when the proliferation probability is about
0.5 10
 6E10
 6. The absorbed doses corresponding to the
probability W(L|V)¼10
 6 for the different cell lines are estimated
from equation (5) and are displayed in Figure 3 from survival
ratios of
3H-thymidine incorporation assays and in Figure 4 from
survival fractions from the MTT assay.
Using the n and D0 data from the proliferation test given in
Table 1, the absorbed dose Dw¼E 6 corresponding to one viable
proliferating cell was calculated. From the results displayed in
Figure 3, the absorbed dose Dw¼E 6 was estimated to be around
100Gy. No significant difference was found in the absorbed dose
Dw¼E 6 for the probability W(L|V)¼10
 6 of cells not affected
between the cases dSa0 and ¼0 for cell proliferation (
3H-
thymidine).
Using the n and D0 data from the cell viability MTT assay in
Table 2, the absorbed dose Dw¼E 6 was estimated to be around
Table 2 Radiation sensitivity parameters n, D0 and dS for irradiated cells obtained from fitting of the MTT assay data of cells from patients GBM1, GBM2,
GBM3, GCG (malignant karyotyped) and N1 (normal karyotyped)
Uncertainty factor
dS¼0 dSa0
Fitting parameters nD 0 (Gy) dSn D 0 (Gy)
Cell lines
GBM1 0.9270.07 171745 0.5970.023 0.4170.04 9.675.0
GBM2 0.9870.08 22.875.9 0.1470.04 0.8670.06 11.673.2
GBM3 0.9970.052 26.973.6 0.1770.04 0.8370.05 13.274.1
Average GBM1–3 0.8670.16 30.078.1 0.1470.03 0.8570.10 12.473.2
GCG 1.0070.04 13.073.4 0.1070.02 0.9170.03 7.172.2
N1(Normal) 0.9970.03 166714 0.2470.31 0.7570.30 108775
The average GBM values are calculated from patients GBM1, GBM2 and GBM3.
Figure 2 Pictures of malignant karyotyped cells from patient GBM2 kept
in culture flasks after irradiation with
137Cs-g radiation at an absorbed dose
of 100Gy. The pictures were taken at day 1 (A), 7 (B), 14 (C) and 20 (D)
after irradiation.
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Figure 3 Adsorbed doses Dw¼E 6 calculated from survival ratios of
3H-
thymidine incorporation assays corresponding to a probability
W(L|V)¼10
 6 (w¼E 6) for cells still being viable after radiation. The
average GBMs are calculated from patients GBM1, GBM2 and GBM3. The
uncertainty bars represent 1s.d. Keys to the abbreviations are given under
the paragraph ‘Karyotyping’.
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l200Gy when using the data obtained at dS¼0, but as high as
800Gy when dSa0. Thus, the cells seem to be viable up to very
high doses. The most critical safety issue is, however, that the cells
injected into the patient do not proliferate. Thus, a hypothetical
absorbed dose around 100Gy is, according to our findings,
sufficient for reaching the negligible probability (10
 6) for cell
division.
In our studies of the plating efficiency, we observed a reduction
in the total number of cells, which means that both cell division
and survival are diminished. There is no visual difference in the
observed cell survival pattern at day 20 in four cell cultures of
malignant karyotype and one of normal karyotype. This observa-
tion confirms that we, in vitro, have apparently normal-looking
cells 1 week after irradiation and that all the cells were dead and
could not form colonies 4 weeks after irradiation, that is, 100Gy is
a safe dose for sterilisation with two million malignant brain
tumour cells to be used for immunisation.
Thus based on the present investigation of the intrinsic cellular
radiation sensitivity of nontransfected cells, we recommend an
absorbed dose of 100Gy for sterilisation of the 2 million cells used
for immunisation of patients in the clinical study.
In the clinical study, the patients’ own tumour cells were
infected with an adenovirus-expressing human IFN-gamma
(100MOI). The day after infection, the transfected cells were
irradiated with 100Gy. The sterilised cells administered to the
patient were examined for the degree of expression of the IFN-g
gene by using ELISA measurements of IFN-g production. The cells
were plated 50000–100000 cells in 24-well plates and media were
collected at different time points. The IFN-g production of the
irradiated cells after days 2, 3, 4 was typically in the order of 1–
5mgml
 1 per million cells.
At the day after transfection, the immunisation of the patient
takes place soon after the cells have been irradiated with 100Gy.
The irradiated cells cannot proliferate but they survive for some
time in the skin of the patient, during which they produce their
abnormal proteins and also the IFN-g. This alerts the immune
system and leads to a production of activated T-lymphocytes,
which have the capability of passing through the blood–brain
barrier. Out in the brain parenchyma, the activated T cells are free
to seek actively for the tumour cells, both in the original tumour
and in the surrounding brain with its migrating ‘guerrilla’ cells
(Salford et al, 2002).
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